Interference with CD47–SIRPα interactions by antagonistic antibodies or CD47 knockdown obviously enhances the in vitro killing of trastuzumab-treated Her-2+ breast cancer cells by phagocytes. The gene discussed is ERBB2; the disease is breast carcinoma.